219 related articles for article (PubMed ID: 21331934)
1. Gynecological cancers.
Avril N; Gourtsoyianni S; Reznek R
Methods Mol Biol; 2011; 727():171-89. PubMed ID: 21331934
[TBL] [Abstract][Full Text] [Related]
2. FDG-PET Assessment of Other Gynecologic Cancers.
Faria S; Devine C; Viswanathan C; Javadi S; Korivi BR; Bhosale PR
PET Clin; 2018 Apr; 13(2):203-223. PubMed ID: 29482750
[TBL] [Abstract][Full Text] [Related]
3. Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET.
Torizuka T; Kanno T; Futatsubashi M; Okada H; Yoshikawa E; Nakamura F; Takekuma M; Maeda M; Ouchi Y
J Nucl Med; 2003 Jul; 44(7):1051-6. PubMed ID: 12843219
[TBL] [Abstract][Full Text] [Related]
4. Positron emission tomography in gynecological malignancies.
Kumar R; Chauhan A; Jana S; Dadparvar S
Expert Rev Anticancer Ther; 2006 Jul; 6(7):1033-44. PubMed ID: 16831075
[TBL] [Abstract][Full Text] [Related]
5. Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer.
Horowitz NS; Dehdashti F; Herzog TJ; Rader JS; Powell MA; Gibb RK; Grigsby PW; Siegel BA; Mutch DG
Gynecol Oncol; 2004 Dec; 95(3):546-51. PubMed ID: 15581961
[TBL] [Abstract][Full Text] [Related]
6. Positron emission tomography with the glucose analog [F]-fluoro-2-deoxy-D-glucose for evaluating pelvic lymph node metastasis in uterine corpus cancer: comparison with CT and MRI findings.
Inubashiri E; Hata K; Kanenishi K; Shiota A; Ohno M; Yamamoto Y; Nishiyama Y; Ohkawa M; Hata T
J Obstet Gynaecol Res; 2009 Feb; 35(1):26-34. PubMed ID: 19215544
[TBL] [Abstract][Full Text] [Related]
7. PET imaging in gynecologic malignancies.
Kumar R; Alavi A
Radiol Clin North Am; 2004 Nov; 42(6):1155-67, ix. PubMed ID: 15488564
[TBL] [Abstract][Full Text] [Related]
8. Role of the integrated FDG PET/CT in the surgical management of patients with high risk clinical early stage endometrial cancer: detection of pelvic nodal metastases.
Signorelli M; Guerra L; Buda A; Picchio M; Mangili G; Dell'Anna T; Sironi S; Messa C
Gynecol Oncol; 2009 Nov; 115(2):231-5. PubMed ID: 19695685
[TBL] [Abstract][Full Text] [Related]
9. A prospective study of the accuracy of 18Fluorodeoxyglucose positron emission tomography (18FDG PET) in identifying sites of metastasis prior to pelvic exenteration.
Husain A; Akhurst T; Larson S; Alektiar K; Barakat RR; Chi DS
Gynecol Oncol; 2007 Jul; 106(1):177-80. PubMed ID: 17477959
[TBL] [Abstract][Full Text] [Related]
10. Novel perioperative imaging with 18F-FDG PET/CT and intraoperative 18F-FDG detection using a handheld gamma probe in recurrent ovarian cancer.
Cohn DE; Hall NC; Povoski SP; Seamon LG; Farrar WB; Martin EW
Gynecol Oncol; 2008 Aug; 110(2):152-7. PubMed ID: 18539314
[TBL] [Abstract][Full Text] [Related]
11. Non-
Kalshetty A; Basu S
PET Clin; 2018 Apr; 13(2):239-248. PubMed ID: 29482752
[TBL] [Abstract][Full Text] [Related]
12. The Role of PET Imaging in Gynecologic Radiation Oncology.
Rao YJ; Grigsby PW
PET Clin; 2018 Apr; 13(2):225-237. PubMed ID: 29482751
[TBL] [Abstract][Full Text] [Related]
13. Fludeoxyglucose F 18 PET-Computed Tomography: Management Changes Effecting Patient Outcomes in Gynecologic Malignancies.
Brunetti JC
PET Clin; 2015 Jul; 10(3):395-409. PubMed ID: 26099674
[TBL] [Abstract][Full Text] [Related]
14. FDG PET/CT in monitoring response to treatment in gynecological malignancies.
Amit A; Person O; Keidar Z
Curr Opin Obstet Gynecol; 2013 Feb; 25(1):17-22. PubMed ID: 23299090
[TBL] [Abstract][Full Text] [Related]
15. Value of fusion of PET and MRI for staging of endometrial cancer: comparison with ¹⁸F-FDG contrast-enhanced PET/CT and dynamic contrast-enhanced pelvic MRI.
Kitajima K; Suenaga Y; Ueno Y; Kanda T; Maeda T; Takahashi S; Ebina Y; Miyahara Y; Yamada H; Sugimura K
Eur J Radiol; 2013 Oct; 82(10):1672-6. PubMed ID: 23727380
[TBL] [Abstract][Full Text] [Related]
16. PET/CT in gynecologic malignancies.
Brunetti J
Radiol Clin North Am; 2013 Sep; 51(5):895-911. PubMed ID: 24010912
[TBL] [Abstract][Full Text] [Related]
17. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
18. Quantitative Assessment of Gynecologic Malignancies.
Tripathy S; Parida GK; Kumar R
PET Clin; 2018 Apr; 13(2):269-288. PubMed ID: 29482754
[No Abstract] [Full Text] [Related]
19. Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis.
Kidd EA; Siegel BA; Dehdashti F; Rader JS; Mutch DG; Powell MA; Grigsby PW
J Clin Oncol; 2010 Apr; 28(12):2108-13. PubMed ID: 20308664
[TBL] [Abstract][Full Text] [Related]
20. [Role of [18F]-fluorodeoxyglucose positron emission tomography for the initial detection, staging, search for recurrences and restaging of gynaecological and breast cancers].
Grahek D; Barranger E; Daraï E; Uzan S; Talbot JN
Gynecol Obstet Fertil; 2005 Jun; 33(6):371-81. PubMed ID: 15927502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
